Compare Cincinnati Financial Corporation (CINF) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cincinnati Financial Corporation vs Sanofi SA — how do they compare? Cincinnati Financial Corporation trades at $173.49 (market cap $26.58B), while Sanofi SA trades at $43.55 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 3.9× Cincinnati Financial Corporation's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| CINF | SNY | |
|---|---|---|
Market Cap | $26.58B | $104.30B |
Sector | Financials | Health |
52-Week High | $192.03 | $52.34 |
52-Week Low | $149.79 | $41.33 |
Enterprise Value | $25.71B | $124.19B |
Dividend Yield | 2.17% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cincinnati Financial (CINF) trades at $173.86, down 1.7% on the day, with a bearish technical signal and key support at $172. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing revenue growth. Strong fundamentals include a low P/E of 8.18, robust ROE of 21.48%, and a consistent dividend history, with a recent H1-26 dividend of $0.94 declared.
The outlook is cautiously optimistic, supported by a consensus price target of $195 and a 'Moderate Buy' analyst rating. Risks include catastrophe losses impacting underwriting and competitive pressures in commercial lines. Positive cash flow trends and rising investment income provide a solid foundation for long-term growth.
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
